Senate Bill 204, which says an "Opioid treatment program" means a program or practitioner engaged in the treatment of ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. In response to these Phase 1 events, Septerna has initiated non ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Understanding why we always have room for dessert could lead to new treatments for obesity, researchers have revealed.

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers have now discovered that what we call the 'dessert stomach' is rooted in the brain. The same ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

In mice, the neurons that dictate the feeling of being full are also the ones that cause sugar cravings, potentially ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 PatientsSHIELD II Enrolled more than ...